SMMT · Summit Therapeutics Inc.
AI read · Bad for SMMT
The AI's read
Summit is left without approval for this treatment in the patient group named in the application. The study delayed cancer worsening, and later follow-up suggested longer survival. But the main survival result did not show a reliable increase in how long patients lived, so the positive results were not enough for the FDA.